These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27926987)

  • 1. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
    Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
    J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
    Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
    Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
    Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
    Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
    Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus for advanced pancreatic neuroendocrine tumors.
    Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
    N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
    Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
    De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G
    J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.
    Pavel ME; Chen D; He W; Cushman S; Voi M; de Vries EGE; Baudin E; Yao JC
    Pancreas; 2017 Jul; 46(6):751-757. PubMed ID: 28609362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
    Bainbridge HE; Larbi E; Middleton G
    Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
    Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
    Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.